Sarcopenia and the GH Axis: What the Research Says About Age-Related Muscle Loss

Adults lose muscle mass steadily from their thirties onwards, and the decline of the growth hormone axis is one contributing mechanism. We review what the evidence currently supports about GH-axis peptides in age-related muscle loss, and what it does not.

By UAE Peptide Clinic Research Desk

Most adults begin losing skeletal muscle from their early thirties, at a rate commonly cited as three to eight per cent per decade. The rate accelerates after sixty. For a long time this was treated as an unavoidable feature of ageing and largely a cosmetic one. That view has changed. Low muscle mass and low muscle strength are now recognised as independent predictors of falls, fractures, insulin resistance, prolonged hospital stays and loss of independence. Understanding what actually drives the decline is the first step in deciding what, if anything, is worth doing about it.

What Sarcopenia Actually Is

Sarcopenia is a clinical diagnosis, not a synonym for looking less muscular. The European Working Group on Sarcopenia in Older People defines it primarily by low muscle strength, confirmed by low muscle quantity or quality, with poor physical performance indicating severity. At the tissue level, the loss is not uniform: type II fast-twitch fibres are lost preferentially, which is why power and the ability to recover from a stumble decline faster than endurance does. Motor unit number also falls, and surviving units take on orphaned fibres less efficiently over time.

Several mechanisms contribute in parallel, which is why single-agent approaches tend to disappoint:

• Anabolic resistance — ageing muscle responds less strongly to the same dose of dietary protein or mechanical load
• Decline of the growth hormone and IGF-1 axis
• Chronic low-grade inflammation, sometimes described as inflammageing
• Mitochondrial dysfunction and reduced oxidative capacity within the fibre
• Falling protein intake, often below the threshold needed to stimulate synthesis
• Reduced physical activity, and particularly reduced resistance loading

The Growth Hormone Axis and Somatopause

Growth hormone secretion falls by roughly fourteen per cent per decade from early adulthood, a pattern sometimes called somatopause. Circulating IGF-1, the downstream mediator of much of GH activity in tissue, declines in parallel. The association between a lower GH-IGF-1 axis and reduced lean mass in older adults is well documented. Whether that decline is a primary cause of sarcopenia, or partly an adaptive response to reduced demand, remains an open question in the literature.

This distinction matters because it has already been tested. Trials of recombinant growth hormone in healthy older adults consistently increased lean body mass and reduced fat mass, but improvements in muscle strength and physical function were inconsistent. Adverse effects — oedema, arthralgia, carpal tunnel syndrome and impaired glucose tolerance — were common at the doses used. The field has since moved away from exogenous GH and towards approaches that work further upstream.

An increase in lean mass does not automatically translate into an increase in strength or function. Clinically, that distinction is the whole point.

Where Peptides Sit in the Current Evidence

Growth hormone secretagogues and GHRH analogues act on the pituitary rather than replacing GH directly, which preserves the body's own pulsatile release pattern and its negative feedback loops. Tesamorelin, a GHRH analogue, carries Phase 3 evidence — but for HIV-associated lipodystrophy, a specific indication, not for age-related muscle loss. Ipamorelin and CJC-1295 have a well-characterised ability to raise GH pulse amplitude in short-term human pharmacology studies, but the data on downstream functional outcomes in older adults is thin. MOTS-C, a mitochondria-derived peptide, has generated interesting preclinical findings on exercise capacity and metabolic signalling, though human trial data remains limited.

Read together, the research supports a narrow set of statements:

• GH-axis peptides can raise endogenous growth hormone and IGF-1 in humans over short observation periods
• Long-term randomised data on strength, falls, gait speed or independence in older adults is not yet available
• No peptide is currently licensed anywhere as a treatment for sarcopenia
• Resistance training and adequate protein intake remain the only interventions with consistent high-quality evidence for reversing age-related muscle loss

Clinical Nuance: Peptides Do Not Replace Load

Muscle protein synthesis is driven by mechanical loading and amino acid availability. Because of anabolic resistance, older adults generally require a higher per-meal protein dose than younger adults to trigger the same synthetic response. A peptide protocol layered on top of a sedentary routine and inadequate protein intake has very little to act on. Physician oversight also matters here for a specific reason: IGF-1 is a growth signal, so appropriate malignancy screening, alongside baseline IGF-1, fasting glucose and HbA1c, forms part of responsible protocol design in this age group.

If you are exploring GH-axis peptides as part of a strategy for maintaining muscle and function with age, our clinical team can review your case, your bloods and your training context — take the 2-minute quiz at /find-my-stack or book a free consultation at /book.